Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors

References

• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. T Lancet Oncol. 2010;11:121–128.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013;19:2584–2591.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–792.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal. 2013;6:re6.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2:922–933.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.
   PubMed Web of Science ®Google Scholar
• de Bruin EC, Cowell C, Warne PH, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014;4:606–619.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67:11924–11932.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120:1145–1154.
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13:528–538.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11:473–481.
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462:1070–1074.
   PubMed Web of Science ®Google Scholar
• Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013;3:1404–1415.
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–1061.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372:1700–1709.
   PubMed Web of Science ®Google Scholar
• Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–1699.
   PubMed Web of Science ®Google Scholar
• Chuang JC, Salahudeen AA, Wakelee HA. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. Expert Opin Pharmacother. 2016;17:989–993.
   PubMed Web of Science ®Google Scholar
• Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010;1804:559–566.
   PubMed Web of Science ®Google Scholar
• Mishani E, Abourbeh G, Jacobson O, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem. 2005;48:5337–5348.
   PubMed Web of Science ®Google Scholar
• Chang S, Zhang L, Xu S, et al. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790→ methionine790 mutant. J Med Chem. 2012;55:2711–2723.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci. 2005;102:7665–7670.
   PubMed Web of Science ®Google Scholar
• Belani CP. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest. 2010;28:413–423.
   PubMed Web of Science ®Google Scholar
• Wong KK. HKI-272 in non–small cell lung cancer. Clin Cancer Res. 2007;13:4593s–4596s.
   PubMed Web of Science ®Google Scholar
• Erlichman C, Hidalgo M, Boni JP, et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2006;24:2252–2260.
   PubMed Web of Science ®Google Scholar
• Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010;70:868–874.
   PubMed Web of Science ®Google Scholar
• Kim Y, Ko J, Cui Z, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11:784–791.
   PubMed Web of Science ®Google Scholar
• Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010;29:2346–2356.
   PubMed Web of Science ®Google Scholar
• Pan Y, Xu Y, Feng S, et al. SKLB1206, a novel orally available multi-kinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4 and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther. 2012;4:952–962.
   Web of Science ®Google Scholar
• Antonello A, Tarozzi A, Morroni F, et al. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. J Med Chem. 2006;49:6642–6645.
   PubMed Web of Science ®Google Scholar
• Wu CH, Coumar MS, Chu CY, et al. Design and synthesis of tetrahydropyridothieno [2, 3-d] pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem. 2010;53:7316–7326.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Seto M, Banno H, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3, 2-d] pyrimidine scaffold. J Med Chem. 2011;54:8030–8050.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Piotrowska Z, Niederst MJ, et al. Osimertinib responses after disease progression in patients who had been receiving rociletinib. JAMA Oncol. 2016;2:541–543.
   PubMed Web of Science ®Google Scholar
• Hedley PL, Jørgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat. 2009;30:1486–1511.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463–469.
   PubMed Web of Science ®Google Scholar
• Trudeau MC, Warmke JW, Ganetzky B, et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269:92–95.
   PubMed Web of Science ®Google Scholar
• Jones EM, Roti EC, Wang J, et al. Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem. 2004;279:44690–44694.
   PubMed Web of Science ®Google Scholar
• Qin M, Wang T, Xu B, et al. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. Eur J Med Chem. 2015;104:115–126.
   PubMed Web of Science ®Google Scholar
• Luo Y, Li Y, Qiu KM, et al. Metronidazole acid acyl sulfonamide: a novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors. Bioorg Med Chem. 2011;19:6069–6076.
   PubMed Web of Science ®Google Scholar
• Patel HM, Bari P, Karpoormath R, et al. Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. RSC Adv. 2015;5:56724–56771.
   Web of Science ®Google Scholar
• https://www.rcsb.org/pdb/explore/explore.do?structureId=4jiu
   Google Scholar
• https://www.rcsb.org/pdb/explore/explore.do?structureId=4zau
   Google Scholar
• Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16:383–390.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47:1750–1759.
   PubMed Web of Science ®Google Scholar
• Evans DA, Doman TN, Thorner DA, et al. 3D QSAR methods: phase and catalyst compared. J Chem Inf Model. 2007;47:1248–1257.
   PubMed Web of Science ®Google Scholar
• Zhong H, Tran LM, Stang JL. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J Mol Graph Mod. 2009;28:336–346.
   PubMed Web of Science ®Google Scholar
• QikProp, version 3.5, Schrödinger, LLC. New York (NY): 2012.
   Google Scholar
• Vistoli G, Pedretti A, Testa B. Assessing drug-likeness–what are we missing? Drug Discov Today. 2008;13:285–294.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3–25.
   Web of Science ®Google Scholar
• Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714–3717.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Duffy EM. Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett. 2000;10:1155–1158.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Delivery Rev. 2002;54:355–366.
   PubMed Web of Science ®Google Scholar